
Dianthus Therapeutics Inc. (NASDAQ:DNTH) released topline data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG).
Claseprubart 300mg and 600mg demonstrated rapid, statistically significant, and clinically meaningful improvements over placebo as measured by both MG-ADL and QMG, including at Week 1 and at Week 13.